Today: 17 May 2026
Unilever share price slips after Deutsche Bank downgrade as valuation bites
9 February 2026
1 min read

Unilever share price slips after Deutsche Bank downgrade as valuation bites

London, February 9, 2026, 08:35 GMT — Regular session

  • Unilever shares slipped at the open in London after Deutsche Bank downgraded the stock to “hold” from “buy”.
  • The broker stuck with its 5,150p target price—still under where the stock most recently traded.
  • Unilever’s results update lands later this week, and investors are watching for any read on volume trends or signals for guidance.

Shares of Unilever slipped Monday, losing 0.7% to 5,214 pence by 0838 GMT, after Deutsche Bank lowered its rating, pointing to what it called a stretched valuation following the stock’s recent rally. Unilever traded between 5,200 and 5,234 pence, down from a Friday close of 5,250 pence.

This downgrade stands out—Unilever’s back in the crowded defensive camp, with shares fully pricing in a neat earnings print. That leaves little room for error: even minor slips in volumes or margins could hit the stock harder than typical, steady sales or not.

Deutsche Bank’s Tom Sykes downgraded Unilever to “hold” from “buy” after the stock pushed past the bank’s 5,150p target, according to a note from the firm. Sykes flagged that Unilever is now sitting at roughly 19 times forward 12-month earnings—a metric that pits price against projected profits—and that’s a 19% premium to the broader market. “The valuation no longer supports a ‘buy’ recommendation,” he wrote. Investing.com

Deutsche Bank’s target price puts the stock only a touch higher than its own fair value estimate. That’s intentional: there’s little room to maneuver if the next set of numbers is just okay.

Unilever, which makes Dove soap and Hellmann’s mayonnaise, has relied on price hikes and mix shifts lately, with some consumers opting for cheaper alternatives. Now, investors are eyeing whether unit sales will start to drive growth as price increases ease.

The implications stretch to the rest of Europe’s staple names. Funds tend to group Nestlé and Reckitt Benckiser alongside Unilever—they’re all seen as “steady cash flow” bets. So when Unilever’s valuation gets thrown into question, that ripple can hit the whole sector quickly, especially with these stocks trading in lockstep.

The risk is clear enough: if the stock keeps floating past target prices ahead of results, another broker downgrade could easily show up, especially if management adopts a more cautious tone. Not a disaster, just a duller outcome — steady company, but a stock that loses its momentum.

Still, a strong outlook with clear margin guidance can outweigh valuation chatter—at least for now—especially if the broader market stumbles and investors swing toward defensive names. That’s the balancing act in this trade.

Unilever’s event calendar pegs its fourth-quarter and full-year 2025 earnings release for Feb. 12, with a slot at the CAGNY consumer conference on Feb. 17.

Stock Market Today

  • Kyoto Financial Group (TSE:5844) Stock Overview and Financial Services
    May 16, 2026, 6:48 PM EDT. Kyoto Financial Group, Inc. (TSE:5844) operates as a holding company managing subsidiaries that provide financial services including deposits, loans, securities trading, and foreign exchange. Based in Kyoto, Japan, the firm focuses on expanding its footprint across domestic and international markets through diversified financial products and services. Its stock performance reflects its position in the evolving financial sector. Investors track TSE:5844 for insights into Japan's regional banking and financial services trends.

Latest articles

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Zeta Global Stock Rises as Snowflake Deal Comes Ahead of Key Vote

Zeta Global Stock Rises as Snowflake Deal Comes Ahead of Key Vote

17 May 2026
Zeta Global shares closed at $17.19, up 3.68% Friday, outperforming major indexes after joining Snowflake’s Open Semantic Interchange data initiative. The stock retreated to $17.14 after hours. Zeta will present at the JPM 2026 Global Technology, Media and Communications Conference on Monday. First-quarter revenue jumped 50% to $396 million, prompting a full-year guidance raise.
Trump’s 2026 tax refunds look bigger — but a smaller IRS could blunt the boost
Previous Story

Trump’s 2026 tax refunds look bigger — but a smaller IRS could blunt the boost

Nvidia’s Jensen Huang calls Meta AI’s profit pioneer as spending fears swirl
Next Story

Nvidia’s Jensen Huang calls Meta AI’s profit pioneer as spending fears swirl

Go toTop